{"id":"revolade","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":{"chemblId":"CHEMBL461101","moleculeType":"Small molecule","molecularWeight":"442.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eltrombopag is a small-molecule, oral TPO receptor agonist that mimics the action of thrombopoietin, a natural hormone that regulates platelet production. By activating TPO receptors on megakaryocyte progenitor cells in the bone marrow, it increases platelet production and raises platelet counts in patients with thrombocytopenia. This mechanism helps restore adequate platelet levels in conditions where platelet production is impaired or platelet destruction is excessive.","oneSentence":"Revolade (eltrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:48.896Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic immune thrombocytopenia (ITP)"},{"name":"Thrombocytopenia in patients with chronic hepatitis C"},{"name":"Severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT06834451","phase":"PHASE4","title":"Bioequivalence Study of Revolade® Eltrombopag 50 mg","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centro de Atencion e Investigacion Medica","startDate":"2025-06-01","conditions":"Healthy, Healthy Donors","enrollment":30},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT04812483","phase":"PHASE2","title":"Immunomodulation With Eltrombopag in ITP","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2022-09-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":2},{"nctId":"NCT06607367","phase":"PHASE1, PHASE2","title":"REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2","status":"NOT_YET_RECRUITING","sponsor":"Melbourne Health","startDate":"2024-10-30","conditions":"Poor Graft Function, Aplastic Anemia Idiopathic","enrollment":20},{"nctId":"NCT06497036","phase":"PHASE3","title":"Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geropharm","startDate":"2023-04-04","conditions":"Drug Effect, Safety Issues, Immunogenicity","enrollment":160},{"nctId":"NCT06045052","phase":"PHASE2","title":"Eltrombopag for Treatment of Fanconi Anemia","status":"COMPLETED","sponsor":"Julian Sevilla","startDate":"2020-12-02","conditions":"Fanconi Anemia","enrollment":8},{"nctId":"NCT01286038","phase":"PHASE1","title":"Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-04-06","conditions":"Myelodysplastic Syndrome (MDS), Thrombocytopenia","enrollment":37},{"nctId":"NCT00909363","phase":"PHASE2","title":"Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-06","conditions":"Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding","enrollment":24},{"nctId":"NCT01439321","phase":"","title":"Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11","conditions":"Immune Thrombocytopenic Purpura","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eltrombopag"],"phase":"marketed","status":"active","brandName":"Revolade®","genericName":"Revolade®","companyName":"Centro de Atencion e Investigacion Medica","companyId":"centro-de-atencion-e-investigacion-medica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Revolade (eltrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow progenitor cells. Used for Chronic immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C, Severe aplastic anemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}